Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline

Movement Disorders

Volumn 28, Issue 8, 2013, Pages 1030-1033

  Reilmann, Ralf ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chorea; Evidence based medicine; Huntington's disease; Therapy

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; HALOPERIDOL; OLANZAPINE; PLACEBO; QUETIAPINE; RILUZOLE; RISPERIDONE; TETRABENAZINE; TIAPRIDE;

ARTICLE; CHOREA; CLINICAL PRACTICE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; GOOD CLINICAL PRACTICE; HUMAN; HUNTINGTON CHOREA; LOW DRUG DOSE; PARKINSONISM; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; UNIFIED HUNTINGTON DISEASE RATING SCALE;

CHOREA; EVIDENCE-BASED MEDICINE; HUNTINGTON'S DISEASE; THERAPY;

CHOREA; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HUMANS; HUNTINGTON DISEASE;

EID: 84881545908     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25500     Document Type: Article

References (15)

1. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2012;79:597-603.
2. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
3. Sitek EJ, Soltan W, Wieczorek D, et al. Self-awareness of motor dysfunction in patients with Huntington's disease in comparison to Parkinson's disease and cervical dystonia. J Int Neuropsychol Soc 2011;17:788-795.
4. Burgunder JM, Guttman M, Perlman S, et al. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease [serial online]. PLoS Curr 2011;3:RRN1260.
5. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003;61:1551-1556.
6. Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007;62:262-272.
7. Suchowersky O, Armstrong MJ, Miyasaki J. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology [serial online]. Neurology 2013; 80:970.
8. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
9. Verhagen ML, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002;59:694-699.
10. O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003;60:996-998.
11. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease [serial online]. Cochrane Database Syst Rev 2009;(3): CD006456.
12. Lucetti C, Gambaccini G, Bernardini S, et al. Amantadine in Huntington's disease: open-label video-blinded study. Neurol Sci 2002;23(suppl 2):S83-S84.
13. Lucetti C, Del DP, Gambaccini G, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2003;60:1995-1997.
14. Heckmann JM, Legg P, Sklar D, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2004;63:597-598.
15. Venuto CS, McGarry A, Ma Q, et al. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 2012;27:31-41.